Charles Bankhead


Authored Items

Clinical Pathways Help Integrate New Drugs, Reduce Variability in Care Delivery

October 2017, Vol 7, No 10 - Clinical Pathways

Chicago, IL—Clinical pathways have an important role in the integration of new cancer drugs into clinical practice. Between January 2015 and mid-2017, the FDA granted more than 60 new approvals in oncology, with new drugs accounting for the vast majority (as opposed to new indications). Staying abreast of new drugs and new indications for specific types of cancer requires much time, which presents an extra burden on community oncologists. [ Read More ]

Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy

July 2017, Vol 7, No 7 - Gynecologic Cancers

National Harbor, MD—Pa­tients with relapsed high-grade ovarian cancer with BRCA mutation derived the greatest benefit from the poly ADP-­ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting. [ Read More ]

Wide Variation in Follow-Up Practices After Neuroendocrine Tumor Resection

April 2017, Vol 7, No 4 - GI Cancers Symposium

San Francisco, CA—Follow-up for completely resected gastroenteropancreatic neuroendocrine tumors (GEP-NETs) varies widely, and the majority of clinicians ignore existing clinical guidelines, an international survey showed, reported Eva Segelov, MBBS (Hons 1), PhD, FRACP, Associate Professor of Medicine, St Vincent’s Clinic, Sydney, New South Wales, Australia, and colleagues, during a poster presentation at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]